GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Cash Flow for Lease Financing

ValiRx (LSE:VAL) Cash Flow for Lease Financing : £-0.01 Mil (TTM As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx Cash Flow for Lease Financing?

ValiRx's Cash Flow for Lease Financing for the six months ended in Jun. 2023 was £-0.01 Mil. ValiRx's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.01 Mil.

Compared with last quarter (£-0.01 Mil in Dec. 2022 ), ValiRx's Cash Flow for Lease Financing remained the same in Jun. 2023 (£-0.01 Mil).


ValiRx Cash Flow for Lease Financing Historical Data

The historical data trend for ValiRx's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Cash Flow for Lease Financing Chart

ValiRx Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -0.01 -0.01

ValiRx Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

ValiRx Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ValiRx Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of ValiRx's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx (LSE:VAL) Business Description

Industry
Traded in Other Exchanges
Address
4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.

ValiRx (LSE:VAL) Headlines

From GuruFocus

Valaris Provides Fleet Status Report

By Business Wire Business Wire 02-21-2023

Oak Hill Advisors LP Reduces Stake in Valaris Ltd

By GuruFocus Research 08-10-2023

Valaris Publishes Sustainability Report

By Business Wire Business Wire 12-15-2022

Valaris Issues Fleet Status Report

By Business Wire 11-01-2023